TABLE 1.

Antifungal susceptibility among clinical bloodstream isolates of Candida species utilized in this study^a

Candida sp. (no. of isolates)	MIC range
	Caspofungin (μg/ml)	Fluconazole (μg/ml)
C. albicans (4)	0.12–0.25	0.12–1
C. tropicalis (4)	0.06–0.25	0.12–2
C. glabrata (4)	0.25	8–16
C. krusei (4)	0.25	32–64
C. parapsilosis (4)	1–2	1–16

^aClinical breakpoints according to CLSI-M27 S4 are as follows (reported in micrograms per milliliter): for caspofungin, ≤0.25 susceptible, 0.5 intermediate, and ≥1 resistant for C. albicans, C. tropicalis, and C. krusei, ≤0.12 susceptible, 0.25 intermediate, and ≥0.5 resistant for C. glabrata, and ≤2 susceptible, 4 intermediate, and ≥8 resistant for C. parapsilosis; for fluconazole, ≤2 susceptible, 4 intermediate, and ≥8 resistant for C. albicans, C. tropicalis, and C. parapsilosis and ≤32 susceptible (dose dependent) and ≥64 resistant for C. glabrata. C. krusei is intrinsically resistant to fluconazole, and all C. krusei fluconazole MIC values are considered to represent resistance.